This document addresses the influence of pharmacogenomics on pharmacovigilance activities. It includes considerations on how to evaluate the pharmacovigilance related issues for medicinal products with pharmacogenomic associations, and how to translate the results of these evaluations to appropriate treatment recommendations in the labelling.
Keywords: Pharmacogenomics, pharmacovigilance, biomarkers, genomic variations
Current effective version
Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products
This guideline addresses the influence of pharmacogenomics on pharmacovigilance activities, including considerations on how to evaluate the pharmacovigilance related issues for medicinal products with pharmacogenomic associations, and how to translate the results of these evaluations to appropriate treatment recommendations in the labelling.
English (EN) (227.64 KB - PDF)
Document history - First version (current)
Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products
This guideline addresses the influence of pharmacogenomics on pharmacovigilance activities, including considerations on how to evaluate the pharmacovigilance related issues for medicinal products with pharmacogenomic associations, and how to translate the results of these evaluations to appropriate treatment recommendations in the labelling.
English (EN) (227.64 KB - PDF)
Overview of comments received on 'Guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products'
English (EN) (347.17 KB - PDF)
Draft guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products
This guideline addresses the influence of pharmacogenomics on pharmacovigilance activities, including considerations on how to evaluate the pharmacovigilance related issues for medicinal products with pharmacogenomic associations, and how to translate the results of these evaluations to appropriate treatment recommendations in the labelling.
English (EN) (188.56 KB - PDF)
Concept paper on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products
Currently, there is limited information on the utilisation of a genomic biomarker during follow up (post marketing) or on the effect of labelling with genomic information. Therefore, guidance is needed on the evaluation of genomic influences during pharmacovigilance activities in order to inform and improve clinical use of specific treatments. It is considered necessary to produce a guideline on the evaluation of pharmacogenomic specific issues in the conduct of pharmacovigilance. Document has republished with revised consultation dates.
English (EN) (65.2 KB - PDF)
Related content
- Multidisciplinary: pharmacogenomics
- Guideline on summary of product characteristics
- Evaluation of anticancer medicinal products in man
- Good pharmacovigilance practices
- ICH E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories
- ICH E16 Genomic biomarkers related to drug response: context, structure and format of qualification submissions
- Methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection
- Pharmacogenomic samples, testing and data handling
- Terminology in pharmacogenetics
- Use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products